Commentary

Video

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

Author(s):

Eric Jonasch, MD

Fact checked by:

Ashling Wahner Kristi Rosa
Conference|ESMO Congress

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses preliminary findings from an ongoing phase 1/2 trial (NCT05119335) investigating the HIF-2α inhibitor NKT-2152 in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC), as well as the potential clinical implications of these data.

Related Videos
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Guillermo Garcia-Manero, MD
Paolo Tarantino, MD
Rahul Banerjee, MD, FACP
Terence W. Friedlander, MD
Yuan Yuan, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Related Content
Renal Cell Carcinoma | Image Credit: © Crystal light - stock.adobe.com
September 17th 2024

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
August 19th 2024

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

Nabil Saba, MD
September 17th 2024

Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma

Shannon N. Westin, MD, MPH, FACOG, professor, clinical medical director, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center
August 15th 2024

FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

Lung cancer
September 16th 2024

Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos

Carlo B. Bifulco, MD, medical director of oncological molecular pathology and pathology informatics at the Providence Oregon Regional Laboratory and CMO of Providence Genomics
September 16th 2024

GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers